-$0.23 EPS Expected for AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) This Quarter

Share on StockTwits

Brokerages expect AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) to report earnings per share of ($0.23) for the current fiscal quarter, Zacks reports. Four analysts have issued estimates for AcelRx Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.24) and the highest estimate coming in at ($0.21). AcelRx Pharmaceuticals reported earnings per share of ($0.21) during the same quarter last year, which indicates a negative year-over-year growth rate of 9.5%. The company is expected to issue its next earnings results on Friday, November 1st.

According to Zacks, analysts expect that AcelRx Pharmaceuticals will report full year earnings of ($0.75) per share for the current fiscal year, with EPS estimates ranging from ($0.79) to ($0.72). For the next financial year, analysts forecast that the business will post earnings of ($0.71) per share, with EPS estimates ranging from ($0.89) to ($0.53). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that follow AcelRx Pharmaceuticals.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last issued its quarterly earnings results on Monday, August 5th. The specialty pharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.23) by $0.07. The business had revenue of $0.94 million for the quarter, compared to analysts’ expectations of $1.55 million.

A number of analysts have issued reports on ACRX shares. Zacks Investment Research lowered shares of AcelRx Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, July 9th. LADENBURG THALM/SH SH reissued a “buy” rating and set a $10.00 price objective on shares of AcelRx Pharmaceuticals in a research report on Thursday, May 9th. Credit Suisse Group began coverage on AcelRx Pharmaceuticals in a research report on Monday, August 5th. They set an “outperform” rating and a $7.00 price objective for the company. ValuEngine downgraded AcelRx Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, May 9th. Finally, BidaskClub downgraded AcelRx Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, May 1st. Four analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $7.47.

NASDAQ:ACRX traded down $0.05 on Friday, reaching $2.20. 811,052 shares of the company’s stock were exchanged, compared to its average volume of 1,028,517. The company has a quick ratio of 11.34, a current ratio of 11.69 and a debt-to-equity ratio of 0.79. The firm has a market capitalization of $178.73 million, a price-to-earnings ratio of -2.72 and a beta of 2.14. The business has a fifty day moving average of $2.49 and a 200-day moving average of $2.89. AcelRx Pharmaceuticals has a 52-week low of $1.99 and a 52-week high of $5.05.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Resources Investment Advisors Inc. acquired a new position in AcelRx Pharmaceuticals in the first quarter valued at approximately $34,000. Parametric Portfolio Associates LLC acquired a new position in AcelRx Pharmaceuticals in the second quarter valued at approximately $26,000. WINTON GROUP Ltd acquired a new position in AcelRx Pharmaceuticals in the second quarter valued at approximately $40,000. Ahrens Investment Partners LLC acquired a new position in AcelRx Pharmaceuticals in the first quarter valued at approximately $108,000. Finally, Weiss Asset Management LP acquired a new position in AcelRx Pharmaceuticals in the first quarter valued at approximately $113,000. 19.13% of the stock is owned by hedge funds and other institutional investors.

About AcelRx Pharmaceuticals

AcelRx Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain.

Read More: What Are Treasury Bonds?

Get a free copy of the Zacks research report on AcelRx Pharmaceuticals (ACRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply